These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 26929305

  • 1. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.
    Ke EE, Wu YL.
    Ther Adv Respir Dis; 2016 Jun; 10(3):256-64. PubMed ID: 26929305
    [Abstract] [Full Text] [Related]

  • 2. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W, Tufman A, Huber RM.
    Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
    [Abstract] [Full Text] [Related]

  • 3. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).
    Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC.
    Patient; 2018 Feb; 11(1):131-141. PubMed ID: 29178024
    [Abstract] [Full Text] [Related]

  • 4. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C.
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
    Vidal ÓJ.
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
    [Abstract] [Full Text] [Related]

  • 7. Afatinib for the treatment of advanced non-small-cell lung cancer.
    Genova C, Rijavec E, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, Grossi F.
    Expert Opin Pharmacother; 2014 Apr; 15(6):889-903. PubMed ID: 24646054
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 10. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
    Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L.
    Lung Cancer; 2014 Aug; 85(2):230-8. PubMed ID: 24929780
    [Abstract] [Full Text] [Related]

  • 11. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D, Popat S.
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [Abstract] [Full Text] [Related]

  • 12. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH.
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [Abstract] [Full Text] [Related]

  • 13. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
    Wislez M, Malka D, Bennouna J, Mortier L, Bensadoun RJ, Sicard J, Dielenseger P, Rey JB, Moro-Sibilot D, Scotté F.
    Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
    [Abstract] [Full Text] [Related]

  • 14. Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
    Amin Z, Jayalie VF, Rajabto W.
    Acta Med Indones; 2017 Jan; 49(1):79-88. PubMed ID: 28450659
    [Abstract] [Full Text] [Related]

  • 15. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
    Engle JA, Kolesar JM.
    Am J Health Syst Pharm; 2014 Nov 15; 71(22):1933-8. PubMed ID: 25349236
    [Abstract] [Full Text] [Related]

  • 16. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
    Protsenko SA, Rudakova AV.
    Vopr Onkol; 2015 Nov 15; 61(4):676-80. PubMed ID: 26571844
    [Abstract] [Full Text] [Related]

  • 17. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M, Okamoto I, Nakagawa K.
    Lung Cancer; 2015 Apr 15; 88(1):74-9. PubMed ID: 25704957
    [Abstract] [Full Text] [Related]

  • 18. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC.
    J Thorac Oncol; 2016 Mar 15; 11(3):380-90. PubMed ID: 26823294
    [Abstract] [Full Text] [Related]

  • 19. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K.
    Ann Oncol; 2017 Feb 01; 28(2):270-277. PubMed ID: 28426106
    [Abstract] [Full Text] [Related]

  • 20. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
    Bowles DW, Weickhardt A, Jimeno A.
    Drugs Today (Barc); 2013 Sep 01; 49(9):523-35. PubMed ID: 24086949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.